Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...
The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19. They have the ability to help the body fight a multitude of diseases, from ...
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...
Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...
Moderna (NASDAQ: MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...
Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...